Company OverviewBriaCell Therapeutics
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat (both provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer.
Top reasons to invest in BriaCell:
• Management & Board are experienced in drug development and capital markets.
• Developing a novel immunotherapy for advanced breast cancer - expected to kill 43000 women in the US in 2021.
• Reported clinical benefits including tumor reductions and survival rates better than those reported in the literature in predictable subsets of patients that were treated with Bria-IMT™ and checkpoint inhibitors.
• Developing an off-the-shelf personalized immunotherapy for advanced breast cancer.
• Recently secured over $50 mil.
Speaker BioPresident, CEO, & Director
BriaCell Therapeutics
Dr. Williams is a seasoned bio-pharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams served as VP of Exploratory Development at Incyte Corporation from 2005 – 2016.
There he facilitated entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).
He was responsible for establishing proof-of-concept in several therapeutic areas, and has been involved in numerous new drug applications (NDAs) for therapeutics that achieved marketing authorization in multiple therapeutic areas including oncology. This includes Jakafi for myelofibrosis and polycythemia vera and baricitinib for rheumatoid arthritis.As Head of Experimental Medicine and VP of Clinical Pharmacology at GlaxoSmithKline, Dr. Williams evaluated several molecules in clinical studies in various therapeutic areas. He ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug development. He supported drug development programs with a wide range of clinical applications. The clinical pharmacology of lapatinib, an orally active drug for breast cancer and other solid tumors, was characterized under his supervision. He was involved in new or supplemental drug authorizations for a number of oncology drugs including Bexxar (lymphoma), Hycamtin (ovarian cancer), and Navelbine (non-small cell lung cancer) as well as ibandronate (Boniva) for osteoporosis. Dr. Williams served as Head of Rheumatology Research at the University of Pennsylvania, ran a major research program in receptor biology, including developing bioactive peptides that mimicked granulocyte-macrophage colony-stimulating factor (GM-CSF), a known stimulant of the immune system. He collaborated with David B. Weiner, Ph.D., a well-known leader in immuno-oncology and vaccine research, in the development of DNA vaccines and was able to bring novel DNA vaccines into the clinic for the treatment of cutaneous T cell lymphoma. Dr. Williams earned his BSc. in Chemistry and Biotechnology from Massachusetts Institute of Technology and Medical Doctorate from Tufts University School of Medicine. Following his residency at the Boston VA Medical Center, Dr. Williams completed fellowship training in Rheumatology and Cellular Immunology at the University of Missouri. He then joined the molecular immunology laboratory of Mark I. Greene, MD, PhD, FRCP, at the University of Pennsylvania, developed novel methods of bioactive peptide design, and collaborated in the study of the activation of the p185/Human epidermal growth factor receptor 2 (HER2) receptor. HER-2 is a protein which is known to promote the growth of cancer cells. Dr. Williams is the named author at over 130 peer reviewed publications, over 15 patents and numerous Investigational New Drugs (INDs) and NDAs.
